TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20831989
Drug: Batroxobin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batroxobin (5 IU through intravenous drip once every alternate day for a total of six doses)
Study: 16309036
Drug: Ketoconazol 400
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazol 400 mg + Clindamycin 100 mg for 6 days (K/C6D)
Study: 16309036
Drug: Ketoconazol 800
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazol 800 mg + Clindamycin 100 mg for 3 days + placebo for 3 days (K/C3D)
Study: 11868797
Drug: Valsartan/hydrochlorothiazide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/hydrochlorothiazide combination (80 mg valsartan o.d. for 4 weeks, then fixed combination if needed)
Study: 11868797
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg o.d. for 4 weeks, then increased to 10 mg if needed)
Study: 9728901
Drug: Combined contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined contraceptive pill (250 microg levonorgestrel plus 30 microg ethinyl estradiol) administered intravaginally, one tablet per week for 8 weeks
Study: 9728901
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen cream (0.625 mg conjugated equine estrogens) administered intravaginally, 1 gm at bedtime, three times in the first week, twice in the second week, and then once a week for the next 6 weeks
Study: 7639971
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose didanosine (200 mg for bodyweight < 60 kg; 134 mg for bodyweight ≥ 60 kg)
Study: 7639971
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose didanosine (750 mg for bodyweight ≥ 60 kg; 500 mg for bodyweight < 60 kg)
Study: 7639971
Drug: Both low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both low and high dose didanosine
Study: 28053896
Drug: Champignon extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Champignon extract 50 mg/day
Study: 28053896
Drug: Champignon extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Champignon extract 500 mg/day
Study: 28053896
Drug: Champignon extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Champignon extract 1000 mg/day
Study: 25565656
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of intravenous hydrocortisone 2 hours prior to surgery
Study: 23493410
Drug: Systematic CRT
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic CRT optimization (at implant, at 3 and 6 months)
Study: 15918057
Drug: Valsartan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (160 mg/day)
Study: 17182977
Drug: HOE‐140 (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOE‐140 (18 μg/kg/h i.v. for 6 h)
Study: 11489570
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate 0.5% twice a day
Study: 11489570
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate 0.5% twice a day and dorzolamide 2% 3 times a day
Study: 28784054
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion according to low-dose standard protocol
Study: 28784054
Drug: Sublingual Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual Misoprostol 25 μg every 4 h
Study: 23043888
Drug: riluzole treatment
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: riluzole treatment for 8 weeks
Study: 18234290
Drug: Enoxaparin (0.67
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (0.67 mg/kg)
Study: 16827700
Drug: sulphadoxine/pyrimethamine (SP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulphadoxine/pyrimethamine (SP), administered up to four times during pregnancy
Study: 8451010
Drug: Cabergoline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.5 mg to 2.5 mg, taken once a day for 8 weeks)
Study: 3953366
Drug: Nicardipine hydrochloride
Normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine hydrochloride (0.5 mg)
Study: 29887287
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg oral CBD
Study: 29887287
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral THC
Study: 22508151
Drug: 57 μg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 57 μg/kg/day r-hGH
Study: 22508151
Drug: 35 μg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 μg/kg/day r-hGH
Study: 19996196
Drug: High-dose pirfenidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pirfenidone (1,800 mg/day)
Study: 19996196
Drug: Low-dose pirfenidone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pirfenidone (1,200 mg/day)
Study: 11898025
Drug: Somatropin (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatropin (0.15 mg/kg/day divided into two equal doses via intramuscular injection)
Study: 7772081
Drug: Colestipol tablets
Normalized name: colestipol Oral Tablet
DrugBank: Colestipol (DB00375)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colestipol tablets 4 g/day
Study: 7772081
Drug: Colestipol tablets
Normalized name: colestipol Oral Tablet
DrugBank: Colestipol (DB00375)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colestipol tablets 16 g/day
Study: 7772081
Drug: Colestipol granules
Normalized name: COLESTIPOL GRANULES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol granules 4 g/day
Study: 7772081
Drug: Colestipol granules
Normalized name: COLESTIPOL GRANULES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol granules 16 g/day
Study: 7438772
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg twice daily, increased to a maximum of 400 mg)
Study: 7438772
Drug: Metoprolol (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (same total dosage as twice-daily regimen, administered once daily)
Study: 2563096
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg once daily
Study: 22789884
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg once daily
Study: 17876251
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Oxycodone and Ibuprofen
Study: 8497169
Drug: enalapril (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril (10-40 mg/d)
Study: 8497169
Drug: atenolol (25-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (25-100 mg/d)
Study: 8497169
Drug: verapamil-retard (120-240
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil-retard (120-240 mg/d)
Study: 8497169
Drug: alphametildopa (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: alphametildopa (250 mg/8h to 3 g/d)
Study: 3580510
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine formulations (10 mg single dose)
Study: 25480874
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (5-FU/LV or capecitabine)
Study: 23323721
Drug: Medication dispensing
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medication dispensing device
Study: 19799779
Drug: Community occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community occupational therapy programme including 10 sessions occupational therapy at home
Study: 19799779
Drug: Community occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community occupational therapy consultation based on information material of the Alzheimer Society
Study: 19799779
Drug: Community occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community occupational therapy programme
Study: 9780942
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment approach
Study: 9780942
Drug: Counseling combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling combined with different occlusal treatments
Study: 8091317
Drug: ZD2138 (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZD2138 (350 mg)
Study: 1571381
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g of cefodizime
Study: 3377456
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of cefodizime
Study: 3377456
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of cefotaxime
Study: 31754065
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally 24 hours prior to procedure and misoprostol 400 μg buccally 2 hours before procedure
Study: 15156528
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (fish oil supplements) - 1.8 g of EPA and 1.2 g of DHA daily for 2 years
Study: 9386869
Drug: TOR240 (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOR240 (240 mg daily)
Study: 9386869
Drug: TAM40 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAM40 (40 mg daily)
Study: 8197648
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of papaverine, phentolamine, and PGE1
Study: 3046409
Drug: Metered Dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered Dose Inhaler (MDI) Bricanyl
Study: 26282650
Drug: Obinutuzumab (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obinutuzumab (1,000 mg)
Study: 25098075
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of movie-based simulation training and traditional verbal training (group A, n = 30)
Study: 21150850
Drug: Remifentanil (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (continuous infusion 0.25 mcg/kg · min)
Study: 21150850
Drug: Fentanyl (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (bolus dose 2.0 mcg/kg)
Study: 9068334
Drug: Intra-articular tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular tenoxicam 20 mg
Study: 10442960
Drug: Intravenous tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tenoxicam
Study: 7786822
Drug: CPT-11 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 administered as a 30-min i.v. infusion according to 3 different schedules: daily for 3 consecutive days every 3 weeks, weekly for 3 weeks, and once every 3 weeks.
Study: 12230222
Drug: Itraconazole (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (50-100 mg d(-1))
Study: 12230222
Drug: Ketoconazole (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200-400 mg d(-1))
Study: 12230222
Drug: Sulfadiazine (100-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadiazine (100-150 mg kg d(-1) up to 6 g d(-1))
Study: 30503111
Drug: D&C plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: D&C plus ACP gel
Study: 24395298
Drug: Hydroxyzine 25
Normalized name: hydroxyzine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 25 mg + Alcohol 0.8 g/kg (HYD + A)
Study: 24395298
Drug: Bilastine 80
Normalized name: bilastine
DrugBank: Bilastine (DB11591)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Bilastine 80 mg + Alcohol 0.8 g/kg (B80 + A)
Study: 24395298
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg + Alcohol 0.8 g/kg (CET + A)
Study: 24395298
Drug: Bilastine 20
Normalized name: Bilastine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilastine 20 mg + Alcohol 0.8 g/kg (B20 + A)
Study: 24395298
Drug: Alcohol 0.8
Normalized name: isopropyl alcohol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 0.8 g/kg alone (ALC)
Study: 12806595
Drug: Enalapril maleate
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril maleate (40 mg/day) for six months
Study: 1739794
Drug: Single high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high dose of vitamin A supplementation
Study: 6340411
Drug: Sucrose high
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose high sodium solution (90 mEq/l)
Study: 6340411
Drug: Sucrose low
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose low sodium solution (58 mEq/l)
Study: 30612511
Drug: Group reminiscence
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group reminiscence therapy with internet-based videos for 60 minutes once a week for 3 months
Study: 20615267
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Fe (ferrous sulphate) daily
Study: 20615267
Drug: Fe plus
Normalized name: PureFe Plus
DrugBank: Zinc sulfate, unspecified form (DB14548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe plus 400 μg folic acid daily
Study: 20615267
Drug: Fe plus
Normalized name: PureFe Plus
DrugBank: Zinc sulfate, unspecified form (DB14548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe plus 2 mg retinol and 1 mg riboflavin daily
Study: 10469179
Drug: Recombinant FVIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant FVIIa (rFVIIa) treatment
Study: 10469179
Drug: Recombinant FVIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant FVIIa (rFVIIa) treatment during surgery
Study: 10469179
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events during treatment episodes
Study: 7502551
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (bismuth subsalicylate, metronidazole, tetracycline plus ranitidine)
Study: 7502551
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (omeprazole and amoxicillin)
Study: 7502551
Drug: Cured H.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cured H. pylori infection (both therapies)
Study: 2138684
Drug: Diclofenac +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac + vitamins B1 (50 mg), B6 (50 mg), B12 (0.25 mg)
Study: 2138684
Drug: Diclofenac (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (25 mg)
Study: 22466021
Drug: Cognitive-behavioural treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural treatment plus usual neck exercises (PTcb group)
Study: 17141491
Drug: Mao-to (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mao-to (0.06 g/kg body wt./dose three times daily)
Study: 17141491
Drug: Oseltamivir (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (2 mg/kg body wt./dose twice daily)
Study: 10069678
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion with free NO availability
Study: 10069678
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion with NO clamp (using L-NMMA)
Study: 10069678
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion with vitamin C co-infusion
Study: 10069678
Drug: Saline control
Normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline control during angiotensin II infusion
Study: 7628024
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg, approximately 1.4 mg.kg‐1 mean) administered at 9:00 pm the night before surgery and at 5:30 am on the morning of surgery
Study: 31784433
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Traditional Chinese Medicine (TCM) and Western medicine (Xin Jia Xuan Bai Cheng Qi Decoction)
Study: 31784433
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy alone (Western standard Medicine)
Study: 28967272
Drug: Initial triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial triple disease-modifying anti-rheumatic drug therapy
Study: 26796681
Drug: Galantamine (AD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (AD G)
Study: 26796681
Drug: Placebo (AD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (AD P+G)
Study: 21626051
Drug: Capecitabine 750
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 750 mg/m² BID for 14 days of a 21-day cycle
Study: 21626051
Drug: Capecitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 1,000 mg/m² BID for 14 days of a 21-day cycle
Study: 21626051
Drug: Capecitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 1,000 mg BID flat dose with continuous dosing of sorafenib 400 mg BID
Study: 19602610
Drug: Twice-daily icodextrin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily icodextrin administration
Study: 19602610
Drug: Once-daily icodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily icodextrin administration
Study: 11790216
Drug: Oral antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antidiabetic agents (various classes)
Study: 11790216
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral antidiabetic agents
Study: 11790216
Drug: Sulfonylureas and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylureas and metformin
Study: 7935701
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (0.5 to 0.6 mg per kilogram of body weight per day)
Study: 7935701
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg per day)
Study: 894086
Drug: Formalin‐inactivated Mycoplasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formalin‐inactivated Mycoplasma pneumoniae vaccine
Study: 24491296
Drug: Unilateral ovarian
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral ovarian suspension for 36-48 hours
Study: 16306060
Drug: Half the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half the recommended dose of vitamin A
Study: 16306060
Drug: Full recommended
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full recommended dose of vitamin A
Study: 11907388
Drug: Paracetamol (P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (P group, n = 8)
Study: 11907388
Drug: Paracetamol and
Normalized name: Paracetamol and tramadol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol and tramadol (PT group, n = 29)
Study: 11907388
Drug: Paracetamol and
Normalized name: Paracetamol and tramadol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol and nalbuphine (PN group, n = 27)
Study: 7654268
Drug: Trimethoprim-sulfamethoxazole, 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole, 160 mg/800 mg twice daily
Study: 7654268
Drug: Nitrofurantoin, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin, 100 mg four times daily
Study: 6605713
Drug: Cefadroxil, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil, 500 mg twice daily
Study: 7654268
Drug: Amoxicillin, 500
Normalized name: Amoxicillin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin, 500 mg three times daily
Study: 1969252
Drug: Dexmedetomidine (optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (optimal dose range)
Study: 31664444
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of 2500 mg of l-citrulline and 250 mg of metformin 3 times a day for 26 weeks
Study: 24592670
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy-based text messaging intervention
Study: 22320028
Drug: Intraoperative ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative ketamine administered as a bolus dose of 0.5 mg/kg in 10 mL of normal saline and a continuous intravenous infusion of 4.0 microg/kg/min
Study: 22320028
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (equal volume to ketamine)
Study: 19772450
Drug: Simplified titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simplified titration algorithm (6 U per meal starting dose, adjusted in 2-U increments)
Study: 19772450
Drug: Intensive titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive titration algorithm (doses based on fasting blood glucose, gender, height, and weight, adjusted based on previous 3 days' mean SMBG)
Study: 19772450
Drug: Intensive titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive titration
Study: 19772450
Drug: Simplified titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simplified titration
Study: 17313424
Drug: 1-month reducing
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month reducing course of oral prednisolone (9 men)
Study: 15198881
Drug: Broncho‐Vaxom (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broncho‐Vaxom (7 mg, oral capsules, one capsule daily for the first 10 days of each month for 3 months)
Study: 15198881
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral capsules, one capsule daily for the first 10 days of each month for 3 months)